• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Philips Respironics launches patient adherence system

Philips Respironics launches patient adherence system

June 15, 2016 By Fink Densford

Philips RespironicsThe Respironics division at Philips (NYSE:PHG) yesterday released the Patient Adherence Management Services designed to support new patients transitioning into continuous positive airway pressure sleep therapy.

The company claims the service can boost sleep patient adherence by16% over the first 30 days of therapy, up to 24% within the first 90 days and an average of 49% for CPAP patients.

“For years, Philips Respironics has provided innovative solutions to help patients with sleep and breathing disorders, always leveraging technology to make therapy feel as natural as possible. Our innovations are connected to intuitively work together at every phase of the health continuum and are designed to enable exceptional outcomes in patient adherence. With this new connected management service, our goal is to help patients fully engage with and adapt to their therapy, ultimately helping them live healthier lives,” Philips behavior change global lead Dr. Mark Aloia said in a press release.

The PAM Service operates on Philips Respironics EncoreAnywhere Software, DreamStation PAP therapy devices and the company’s portfolio of masks and the DreamMapper patient engagement application,the company said.

The program includes personalized calls, emails and texts intended to educate, motivate and support sleep therapy patients, software for workflow and communications with home care providers to help identify struggling patients and customized patient engagement apps.

In March, Respironics agreed to pay $34.8 million to settle U.S. Justice Dept. claims that it paid kickbacks in the form of free call center services to induce suppliers into buying its sleep apnea masks.

The settlement resolves a whistleblower lawsuit filed by South Carolina pharmacist Dr. Gibran Ameer, who worked for medical equipment suppliers that bought the Respironics masks.

Federal prosecutors said Respironics violated the federal False Claims Act with its “Fit for Life” program from April 2012 to November 2015, provided to suppliers so long as their patients used its masks.

Filed Under: Business/Financial News, Patient Monitoring, Respiratory Tagged With: Philips, Respironics Inc.

More recent news

  • A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
  • Dexcom continues advances in AI for CGM, type 2 diabetes awareness
  • Tandem continues to deliver more options, benefits for those with diabetes
  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy